Evista (raloxifene) might help prevent breast cancer in postmenopausal women

New research suggests that Evista (raloxifene) might help prevent breast cancer in postmenopausal women.

Women taking Evista for osteoporosis seem to have a 60% lower risk of developing breast cancer. This may turn out to be similar to the benefit that's seen with tamoxifen.

Tamoxifen REDUCES the incidence of breast cancer up to 50% in high-risk women...but it INCREASES the risk of endometrial cancer.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote